Skip to content

Comment on Toshiba device tests cancer types from a drop of bloodparent

Comments

This is part of the damage Theranos has done. Even when a legitimate advance comes along in the same field, people are reluctant to believe it because of the hype that Theranos created.

Not exactly. What Theranos has done is to make clear in its aftermath why the problem of making a diagnosis from a single drop of blood is difficult. In short, the sample size is too small and may not contain biomarkers of the diseases of interest even if they are present in the body. Unless this advancement in its application can show how and why this is not a problem, there will be resistance towards accepting what is being put out without further substantiating evidence.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.